The associations of circulating 20S proteasomes (c20S) with clinical and serologic disease indices in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD) are unknown. We present the initial report that c20S levels are elevated in MCTD and correlate with clinically relevant changes in disease activity in SLE and MCTD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2546673 | PMC |
| http://dx.doi.org/10.1128/CVI.00187-08 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Label-Free Microfluidic Apheresis of Circulating Tumor Cell Clusters.
Adv Sci (Weinh)
October 2024
Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Boston, MA, 02129, USA.
Screening liters of blood (i.e., apheresis) represents a generalized approach to promote the reliable access to circulating tumor cell clusters (CTCCs), which are known to be highly metastasis-competent, yet ultrarare.
View Article and Find Full Text PDFOutcomes According to Coronary Disease Complexity and Optimal Thresholds to Guide Revascularization Approach: FAME 3 Trial.
JACC Cardiovasc Interv
August 2024
Stanford University School of Medicine, Stanford, California, USA; VA Palo Alto Medical Systems, Palo Alto, California, USA. Electronic address:
Background: Coronary disease complexity is commonly used to guide revascularization strategy in patients with multivessel disease (MVD).
Objectives: The aim of this study was to assess the interactive effects of coronary complexity on percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) outcomes and identify the optimal threshold at which PCI can be considered a reasonable option.
Methods: A total of 1,444 of 1,500 patients with MVD from the FAME (Fractional Flow Reserve versus Angiography for Multi-vessel Evaluation) 3 randomized trial were included in the analysis (710 CABG vs 734 PCI).
PRCP is a promising drug target for intracranial aneurysm rupture supported via multi-omics analysis.
Stroke Vasc Neurol
August 2024
Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Background: Cerebral aneurysms are life-threatening cerebrovascular disorders. Currently, there are no effective treatments for preventing disease progression. Mendelian randomisation (MR) is widely used to repurify licensed drugs and identify new therapeutic targets.
View Article and Find Full Text PDFClinical Features and Treatment Outcomes in Patients in Their Twenties with Ischemic Moyamoya Disease.
Cerebrovasc Dis Extra
September 2024
Department of Neurosurgery, School of Medicine, Iwate Medical University, Yahaba, Japan.
Introduction: Revascularization surgery is recommended for all pediatric patients with moyamoya disease (MMD) with ischemic symptoms because the brains of such patients are still developing. By contrast, no clear guidelines for selective revascularization surgery in adult patients (30 years or more) with ischemic presentation have been established. Regarding the age of initial onset of ischemic MMD, patients in their 20s are at the bottom of the distribution and this age group may share features with both adult and pediatric patients.
View Article and Find Full Text PDFA synovial cyst-induced vertebral artery dissection in bow hunter's stroke: illustrative case.
J Neurosurg Case Lessons
August 2024
Department of Neurosurgery, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan.
Background: Bow hunter's stroke (BHS) is a rare condition characterized by occlusion of the vertebral artery (VA) due to a head rotation. BHS typically results from neck hyperrotation, often due to anatomical factors. The authors present a case of BHS in a young male patient exacerbated by os odontoideum (OD), resulting in atlantoaxial dislocation, which ultimately led to VA dissection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!